Does Medroxyprogesterone Interact with Pegvaliase Pqpz?
Medroxyprogesterone and Pegvaliase Pqpz have a unknown drug interaction according to U.S. FDA drug labeling data. ( 7.1 ) 7.1 Effect of PALYNZIQ on Other PEGylated Products In a single dose study of PALYNZIQ in adult patients with PKU, two patients receiving concomitant injections of medroxyprogesterone acetate suspension (a formulation containing PEG 3350) experienced a hypersensitivity reaction. One of the two patients experienced a hypersensitivity reaction on day 15 after a single PALYNZIQ dosage of 0.67 mg within 15 minutes following medroxyprogesterone acetate injectable suspension, and subsequently experienced anaphylaxis on day 89 within 30 minutes after the next dose of medroxyprogesterone acetate injectable suspension. The other patient experienced a hypersensitivity reaction on day 40 after a single PALYNZIQ dosage of 0.08 mg within 10 minutes following medroxyprogesterone acetate injectable suspension. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Unknown
- Pegvaliase Pqpz Class
- Phenylalanine Metabolizing Enzyme
- Management
- Consult your pharmacist
- Data Source
- U.S. FDA via OpenFDA
What To Tell Your Doctor or Pharmacist
If you are taking Medroxyprogesterone and your doctor is considering prescribing Pegvaliase Pqpz (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Never stop or change either medication without first consulting your healthcare provider